Clearbridge BioMedics is a spin-off from the National University of Singapore that focuses on applications of oncology research and diagnostics. They are striving to provide a non-invasive “liquid biopsy” tool, moving into the next generation for cancer screenings, diagnoses, staging, personalised medicine, and treatment monitoring.  They plan to use a label-free Circulating Tumour Cell (CTC) enrichment platform to make this vision a reality .
While the technology prototype is currently being used for cancer research and clinical trials, researchers are hopeful that it will help them better understand the biology of cancer and gain understanding about the disease. In turn, this should help improve patient management. 
With their innovative ideas a research background, Clearbridge BioMedics has joined the CANCER-ID consortium. This group is a public and private international consortium that plans to set up standardised protocols for and the clinical validation of blood-based biomarkers.  Clearbridge BioMedics is the first partner that is headquartered in Asia, bringing the total number of partners to 38 .